Sanofi India posts 27% growth in operating profits in Q1 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Standalone profit from operations for the quarter were Rs. 162 crores
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The Q1 2025 also witnessed a successful launch of Allegra D
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated